Health Catalyst , Inc. (NASDAQ:HCAT) Chief Financial Officer, Jason Alger, has recently sold a portion of his company shares, according to the latest SEC filings. On September 6, 2024, Alger sold 2,899 shares of Health Catalyst common stock at a price of $7.3911 per share, totaling over $21,426.
The transaction was executed under a Rule 10b5-1 trading plan, which was established by Alger on March 13th, 2024. This type of plan allows company insiders to set up a predetermined schedule for buying or selling stocks at a time when they are not in possession of material non-public information, providing a defense against claims of insider trading.
Following the sale, Alger still owns a substantial number of Health Catalyst shares, with 114,106 shares remaining in his possession. The company, known for its data processing and computer programming services, has its headquarters in South Jordan, Utah.
Investors often monitor insider sales as they may provide insights into an executive's perspective on the company's current valuation or future prospects. However, it's important to note that insider sales can be motivated by a variety of personal financial needs or portfolio diversification strategies and not necessarily due to a negative outlook on the company.
Health Catalyst has not made any public statements regarding this recent transaction by their CFO. Investors and analysts may continue to watch the company's performance and any future insider transactions for indications of Health Catalyst's trajectory.
In other recent news, Health Catalyst Inc. continues to make significant strides in the healthcare data analytics market. The company reported robust Q2 2024 earnings, with revenue reaching $75.9 million, a 4% year-over-year increase, and adjusted EBITDA hitting $7.5 million. These figures surpassed the company's financial guidance, indicating a strong first half of 2024.
Canaccord Genuity maintained a Buy rating and an $11.00 price target on Health Catalyst shares, following the company's earnings report. Piper Sandler, another analyst firm, adjusted its outlook on Health Catalyst, reducing the price target to $11 from $14 while retaining an Overweight rating. Both firms recognize the company's strong performance and potential for growth.
Health Catalyst has also completed acquisitions worth $61.2 million from May to August, enhancing its market position. Despite a client's bankruptcy proceedings, the company maintains its full-year adjusted EBITDA guidance. The company's management expressed optimism regarding growth prospects, especially with the introduction of the Health Catalyst Ignite platform. The company anticipates a return to double-digit revenue growth in 2025. These are among the recent developments that reflect Health Catalyst's strategic focus and potential for continued growth.
InvestingPro Insights
As investors digest the news of CFO Jason Alger's recent stock sale of Health Catalyst, Inc. (NASDAQ:HCAT), it's beneficial to consider the company's financial health and market performance. Health Catalyst holds more cash than debt on its balance sheet, which is a reassuring sign of financial stability. Additionally, analysts anticipate that the company's net income is expected to grow this year, suggesting potential for future profitability despite the recent insider sale.
Looking at the company's performance over the last few months, Health Catalyst has demonstrated a significant return, with an 18.05% increase over the last month and a 17.51% rise over the last three months. These figures highlight a strong short-term performance, which may be of interest to investors considering the company's stock.
In terms of valuation, Health Catalyst has a market capitalization of approximately $473.48 million, and while the company has a negative P/E ratio of -5.23, this is not uncommon for companies investing heavily in growth. The revenue growth has been modest, with a 5.23% increase over the last twelve months as of Q2 2024, which may indicate a steady progress in expanding the company's operations.
For those looking for more in-depth analysis, there are additional InvestingPro Tips available, which can provide further context on Health Catalyst's financial outlook and stock performance. Interested readers can find a total of 9 tips on the company by visiting the InvestingPro platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.